212 related articles for article (PubMed ID: 20164500)
21. Regulation of mouse Heparanase gene expression in T lymphocytes and tumor cells.
de Mestre AM; Soe-Htwe T; Sutcliffe EL; Rao S; Pagler EB; Hornby JR; Hulett MD
Immunol Cell Biol; 2007; 85(3):205-14. PubMed ID: 17213834
[TBL] [Abstract][Full Text] [Related]
22. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression.
Cohen-Kaplan V; Doweck I; Naroditsky I; Vlodavsky I; Ilan N
Cancer Res; 2008 Dec; 68(24):10077-85. PubMed ID: 19074873
[TBL] [Abstract][Full Text] [Related]
23. Crosstalk between tumor cells and lymphocytes modulates heparanase expression.
Theodoro TR; Matos LL; Cavalheiro RP; Justo GZ; Nader HB; Pinhal MAS
J Transl Med; 2019 Mar; 17(1):103. PubMed ID: 30922347
[TBL] [Abstract][Full Text] [Related]
24. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.
Reiland J; Kempf D; Roy M; Denkins Y; Marchetti D
Neoplasia; 2006 Jul; 8(7):596-606. PubMed ID: 16867222
[TBL] [Abstract][Full Text] [Related]
25. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
26. Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1.
de Mestre AM; Khachigian LM; Santiago FS; Staykova MA; Hulett MD
J Biol Chem; 2003 Dec; 278(50):50377-85. PubMed ID: 14522979
[TBL] [Abstract][Full Text] [Related]
27. Heparanase is involved in proliferation and invasion of ovarian cancer cells.
Zheng H; Ruan J; Zhao P; Chen S; Pan L; Liu J
Cancer Biomark; 2015; 15(5):525-34. PubMed ID: 25586097
[TBL] [Abstract][Full Text] [Related]
28. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases.
Zcharia E; Jia J; Zhang X; Baraz L; Lindahl U; Peretz T; Vlodavsky I; Li JP
PLoS One; 2009; 4(4):e5181. PubMed ID: 19360105
[TBL] [Abstract][Full Text] [Related]
29. Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Hoß SG; Grundmann M; Benkel T; Gockel L; Schwarz S; Kostenis E; Schlesinger M; Ilan N; Vlodavsky I; Bendas G
Thromb Haemost; 2018 Oct; 118(10):1803-1814. PubMed ID: 30235481
[TBL] [Abstract][Full Text] [Related]
30. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
31. Smad4 suppresses the tumorigenesis and aggressiveness of neuroblastoma through repressing the expression of heparanase.
Qu H; Zheng L; Jiao W; Mei H; Li D; Song H; Fang E; Wang X; Li S; Huang K; Tong Q
Sci Rep; 2016 Sep; 6():32628. PubMed ID: 27595937
[TBL] [Abstract][Full Text] [Related]
32. SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer.
Li QW; Zhang GL; Hao CX; Ma YF; Sun X; Zhang Y; Cao KX; Li BX; Yang GW; Wang XM
J Ethnopharmacol; 2021 Feb; 266():113430. PubMed ID: 33011366
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
34. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells.
de Mestre AM; Rao S; Hornby JR; Soe-Htwe T; Khachigian LM; Hulett MD
J Biol Chem; 2005 Oct; 280(42):35136-47. PubMed ID: 16093249
[TBL] [Abstract][Full Text] [Related]
35. Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1.
de Mestre AM; Staykova MA; Hornby JR; Willenborg DO; Hulett MD
J Leukoc Biol; 2007 Nov; 82(5):1289-300. PubMed ID: 17656651
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
37. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
38. Dominant-negative CREB inhibits heparanase functionality and melanoma cell invasion.
Aucoin R; Reiland J; Roy M; Marchetti D
J Cell Biochem; 2004 Oct; 93(2):215-23. PubMed ID: 15368349
[TBL] [Abstract][Full Text] [Related]
39. Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity.
Liu XY; Tang QS; Chen HC; Jiang XL; Fang H
Int J Biol Sci; 2013; 9(6):564-77. PubMed ID: 23847439
[TBL] [Abstract][Full Text] [Related]
40. A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.
Eladdadi A; Isaacson D
Bull Math Biol; 2008 Aug; 70(6):1707-29. PubMed ID: 18648887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
